PRODUCTS
SERVICES
The primary investment objective of the scheme is to seek to generate consistent returns bypredominantly investing in equity and equity related securities of pharmaceutical and healthcarecompanies.
1.93
6 yrs 4 m
0.5%
3,018.76 Crs
0.50% on or before 1M, Nil after 1M
Mid Growth
7.05
SIP 100 & Lumpsum 100
NA
Chirag Dagli
Investors understand that their principal will be at very high risk